Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes

Berneis, Kaspar; Jeanneret, Christina; Muser, Jürgen; Felix, Barbara; Miserez, André R.

doi:10.1016/j.metabol.2004.08.017

Cited by 87 publications

(75 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, very small LDL cholesterol levels were a very important variable for predicting baPWV in the IGM group, although neither total cholesterol nor LDL cholesterol levels were as closely associated with baPWV as were triglycerides. LDL particle size was clinically the strongest predictor for carotid intima-media thickness in patients with type 2 diabetes, as reported previously by our laboratory 10) and others 31) . Although the exact mechanism is unknown, the artery may be easily invaded by smaller LDL particles under conditions with IGM.…”

Section: Discussionsupporting

confidence: 88%

Very Small Low-Density Lipoprotein Cholesterol Level is a Determinant of Arterial Stiffness in Men with Impaired Glucose Metabolism

Takahashi¹,

Imamura

Yoshikane³

et al. 2010

JAT

View full text Add to dashboard Cite

Aim:Pulse wave velocity (PWV), an estimate of arterial stiffness, is an important predictor of cardiovascular risk. The aim of this study was to investigate the relationship between lipoprotein subclasses and brachial-ankle PWV (baPWV). Methods: A total of 131 apparently healthy Japanese men without a history of cardiovascular disease were divided into two groups: normal glucose metabolism (n 87) and impaired glucose metabolism (n 44). Cholesterol concentrations of major lipoproteins and their subclasses were determined by HPLC with gel permeation columns. Results: In the normal glucose metabolism group, age, systolic blood pressure, and diastolic pressure were associated with increased baPWV, and a stepwise multiple linear regression analysis revealed that age (p 0.022) and systolic blood pressure (p 0.001) were significantly independent determinants of baPWV. In the impaired glucose metabolism group, age (p 0.002), very small LDL cholesterol (p 0.012), systolic blood pressure (p 0.021), and the fasting plasma glucose concentration (p 0.038) were identified as independent determinants of baPWV, although a univariate analysis revealed significant relationships of several plasma lipid compositions or species to baPWV. Conclusions: In addition to aging, hypertension and glucose levels, very small LDL cholesterol levels appear to play an important role in the development of arterial stiffness in men with impaired glucose metabolism.

show abstract

Section: Discussionsupporting

confidence: 88%

Very Small Low-Density Lipoprotein Cholesterol Level is a Determinant of Arterial Stiffness in Men with Impaired Glucose Metabolism

Takahashi¹,

Imamura

Yoshikane³

et al. 2010

JAT

View full text Add to dashboard Cite

show abstract

“…Decreasing the number of sdLDL particles has been shown to be a stronger predictor of regression of coronary stenosis than lowering LDL-cholesterol levels. 7 Furthermore, sdLDL is a better predictor of coronary heart disease (CHD) than other lipid parameters (including LDL apo B and HDL-cholesterol) in patients with T2DM 11 and is associated with other metabolic disorders, including insulin resistance, which increase CVD risk.…”

Section: Introductionmentioning

confidence: 99%

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Murdoch

Parikh

et al. 2006

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

A substantial number of individuals with type 2 diabetes mellitus (T2DM) demonstrate a predominance of small dense low-density lipoprotein (sdLDL), which is associated with an increased risk of cardiovascular disease (CVD). In some cases, sdLDL persists after treatment with a statin to reduce levels of LDL. The effect of the addition of a thiazolidinedione, rosiglitazone (RSG) (4 mg/day or 8 mg/day) to statin therapy on LDL phenotype and C reactive protein (CRP) levels was investigated in a 12-week, placebo-controlled study of 72 T2DM patients who were well controlled and on a statin, but who had persistently predominant sdLDL.Addition of RSG 8 mg to statin therapy significantly increased LDL buoyancy (relative flotation +0.014, p=0.003) and LDL particle size (+4.2Å, p=0.001) from baseline and relative to the change with placebo (+0.014 and +3.8Å; p=0.03 and p=0.04, respectively), and was associated with a non-significant decrease in sdLDL. RSG 8 mg moderately, but significantly, increased total cholesterol (by 12.2%, p=0.004), LDL-cholesterol (11.2%, p=0.02) and intermediate-density lipoprotein (IDL)-cholesterol from baseline but did not increase total or LDL apolipoprotein B. RSG 4 mg and 8 mg significantly reduced CRP compared with placebo (-44.9% and -48.0%; p=0.008 and p=0.004, respectively), and significantly reduced insulin resistance and fasting plasma glucose from baseline.Addition of RSG to statin therapy may further reduce cardiovascular risk by improving the LDL phenotype, as well as reducing insulin resistance and CRP levels. However, the increase in IDL may be proatherogenic and must be considered when assessing the benefits of rosiglitazone. 2006;3:189-96 Diabetes Vasc Dis Res

show abstract

“…21 Another study reported that type 2 diabetic patients with coronary artery disease had significantly higher sdLDL levels than healthy controls. 22 However, contradictory results regarding the relevance of sdLDL to diabetic microvascular complications have been observed. 4,5,8,10,24,25 Although, similar to our research, …”

Section: Resultsmentioning

confidence: 99%

Effects of Small Dense LDL in Diabetic Nephropathy in Females with Type 2 Diabetes Mellitus

Ryu

Kim

et al. 2016

J Lipid Atheroscler

View full text Add to dashboard Cite

Objective: This study investigated the association between small-dense low-density lipoprotein (sdLDL) and diabetic nephropathy (DN) in type 2 diabetic patients. Methods: A total of 172 type 2 diabetic patients (95 men and 77 women) who had not taken lipid-lowering agents were enrolled in this study. Measured LDL cholesterol fractionates into seven parts (LDL1 through 7) according to the size and the extent of charge. Using this system, we analyzed mean LDL particle size and the proportion of sdLDL (the percent of LDL3 through 7 over whole LDL). DN was defined as the albumin-to-creatinine ratio (ACR) ≥30 mg/g after excluding other causes of proteinuria.

show abstract

Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes

Cited by 87 publications

References 42 publications

Very Small Low-Density Lipoprotein Cholesterol Level is a Determinant of Arterial Stiffness in Men with Impaired Glucose Metabolism

Very Small Low-Density Lipoprotein Cholesterol Level is a Determinant of Arterial Stiffness in Men with Impaired Glucose Metabolism

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Effects of Small Dense LDL in Diabetic Nephropathy in Females with Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About